Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DB82TO
|
|||
| Drug Name |
Tofisopam
|
|||
| Synonyms |
tofisopam; 22345-47-7; Grandaxin; Seriel; 1-(3,4-Dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine; Egyt 341; Tofisopamum; 5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-; tofizopam; NCGC00165912-02; 1-(3,4-Dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-benzo[d][1,2]diazepine; benzodiazepine; EGYT 341; Grandaxin; Nodeprine; Seriel; Tofisopamum [INN-Latin]; 7,8-Dimethoxy-1-(3,4-dimethoxyphenyl)-5-ethyl-4-methyl-5H-2,3-benzodiazepine; Tofisopam [INN:DCF:JAN]; EINECS 244-922-3; CCRIS 8738; Emandaxin (TN); DSSTox_CID_3681; Tofisopam (JP17/INN); DSSTox_RID_77145; DSSTox_GSID_23681; SCHEMBL43522; Tofisopam (patented in japan); CHEMBL404216; SCHEMBL8086894; DTXSID3023681; CHEBI:32241; BCP09600; Tox21_112269; MFCD00823171; Tofisopam, >=98% (HPLC), solid; AKOS025401672; DB08811; QC-1212; NCGC00165912-01; NCGC00165912-03; AC-24288; LS-14948; CAS-22345-47-7; DB-045872; FT-0638212; X6663; D01254; 345T477; Q945537; Q-201839; BRD-A69095630-001-01-1; 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine; 1-[3,4-bis(methyloxy)phenyl]-5-ethyl-4-methyl-7,8-bis(methyloxy)-5H-2,3-benzodiazepine; (1Z,3Z)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-benzo[d][1,2]diazepine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hyperuricaemia [ICD-11: 5C55.Y] | Phase 2 | [1] | |
| Irritable bowel syndrome [ICD-11: DD91.0; ICD-10: K55-K64, K58; ICD-9: 564.1, 787.91] | Phase 2 | [2] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H26N2O4
|
|||
| Canonical SMILES |
CCC1C(=NN=C(C2=CC(=C(C=C12)OC)OC)C3=CC(=C(C=C3)OC)OC)C
|
|||
| InChI |
1S/C22H26N2O4/c1-7-15-13(2)23-24-22(14-8-9-18(25-3)19(10-14)26-4)17-12-21(28-6)20(27-5)11-16(15)17/h8-12,15H,7H2,1-6H3
|
|||
| InChIKey |
RUJBDQSFYCKFAA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 22345-47-7
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:32241
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 10A (PDE10) | Target Info | Inhibitor | [3] |
| Phosphodiesterase 2A (PDE2A) | Target Info | Inhibitor | [3] | |
| Phosphodiesterase 3 (PDE3) | Target Info | Inhibitor | [3] | |
| Phosphodiesterase 4A (PDE4A) | Target Info | Inhibitor | [3] | |
| KEGG Pathway | Purine metabolism | |||
| Morphine addiction | ||||
| cAMP signaling pathway | ||||
| cGMP-PKG signaling pathway | ||||
| NetPath Pathway | TSH Signaling Pathway | |||
| Pathwhiz Pathway | Purine Metabolism | |||
| Reactome | cGMP effects | |||
| G alpha (s) signalling events | ||||
| DARPP-32 events | ||||
| WikiPathways | G Protein Signaling Pathways | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01519687) Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT00486876) A Study of 3 Doses of Dextofisopam in Females With Irritable Bowel Syndrome. U.S. National Institutes of Health. | |||
| REF 3 | The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.